Table 1B. Treated patient characteristics (IDS and relapse).

Patient number	Age	Treatment post sample	FIGO stage	PFI months	Clinical Category	PFS months	Sample type
3	48	Carboplatin/paclitaxel	3c	NA	IDS	15	Solid tumour
15	51	Carboplatin/paclitaxel	4	NA	IDS	>36	Solid tumour
18	63	Carboplatin/paclitaxel	4	NA	IDS	11	Solid tumour
34	70	Carboplatin/paclitaxel	3c	NA	IDS	9	Ascites
35	53	Etoposide	4	NA	IDS	11	Solid tumour
43	69	Cisplatin/etoposide	3c	NA	IDS	0	Ascites
44	80	Carboplatin	3c	NA	IDS	>6	Ascites
1	53	Carboplatin	4	24	>6monthsa	5	Ascites
4	59	Carboplatin	4	27	>6months	9	Ascites
14	57	Topotecan	3c	8	>6months	0	Ascites
7	68	Topotecan	3c	6	<6monthsa	11	Ascites
10	71	Liposomal doxorubicin	3c	4	<6months	4	Ascites
11	56	Liposomal doxorubicin	3c	2	<6months	0	Solid tumour
13	75	Carboplatin/gemcitabine	4	0	<6months	0	Ascites
16	80	Noneb	3c	0	<6months	0	Ascites
17	66	None	3c	3	<6months	0	Ascites
22	69	Noneb	4	0	<6months	0	Ascites
27	54	Noneb	3c	0	<6months	0	Ascites
31	49	Carboplatin/paclitaxel	3c	4	<6months	0	Ascites
39	58	Cisplatin/etoposide	4	0	<6months	>6	Ascites
41	63	Noneb	4	4	<6months	0	Ascites
47	77	Noneb	3c	0	<6months	NA	Ascites

Abbreviations: IDS=interval debulking surgery; NA=not applicable; PFI=platinum-free interval; PFS=progression-free survival.

^aClinical category of relapse determined by the PFI is used to decide about likelihood of a response to further platinum-based chemotherapy.

^bPatients relapsed on carboplatin chemotherapy.